Erratum: Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas (Cell Physiol Biochem (2013) 31 (379-388) DOI: 10.1159/000343375);Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas

Cellular Physiology and Biochemistry

Volumn 31, Issue 2-3, 2013, Pages 379-388

  Peng, Hu ^a   Fan, Jingping ^a   Wu, Jian ^a   Lang, Juntian ^a   Wang, Junyu ^a   Liu, Huanhai ^a   Zhao, Shuwei ^a   Liao, Jianchun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; HEPN1; Invasion; Pituitary somatotroph adenomas; Proliferation

Indexed keywords

GELATINASE A; GELATINASE B; HEPATOCELLULAR CARCINOMA DOWN REGULATED 1 PROTEIN; PROTEIN BCL 2; SHORT HAIRPIN RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS ASSAY; ARTICLE; CELL INVASION; CELL POPULATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; PITUITARY SOMATOTROPH ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

LENTIVIRUS;

EID: 84875651568     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.33594/000000597     Document Type: Erratum

References (24)

1. Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.
2. Vandeva S, Jaffrain-Rea ML, Daly AF, Tichomirowa M, Zacharieva S, Beckers A: The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2010;24:461-476.
3. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB: Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-3099.
4. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, Wierman ME, Kleinschmidt-DeMasters BK: Giant pituitary adenomas: Pathologic-radiographic correlations and lack of role for p53 and mib-1 labeling. Am J Surg Pathol 2011;35:1204-1213.
5. Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P: Giant pituitary tumors: A study based on surgical treatment of 118 cases. Surg Neurol 2004;61:436-445; discussion 445-436.
6. Webb SM: Pituitary tumors: Coping with 'cured' pituitary tumors. Nat Rev Endocrinol 2011;7:251-252.
7. Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM, Laws ER: Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 2008;11:37-48.
8. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M: Biomarkers of pituitary neoplasms: A review (part ii). Neurosurgery 2010;67:1790-1798; discussion 1798.
9. Asa SL, Ezzat S: The pathogenesis of pituitary tumors. Annu Rev Pathol 2009;4:97-126.
10. Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011;7:257-266.
11. Dworakowska D, Korbonits M, Aylwin S, McGregor A, Grossman AB: The pathology of pituitary adenomas from a clinical perspective. Front Biosci 2011;3:105-116.
12. Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M, Asa SL: Inactivation of rassf1a tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 2005;85:464-473.
13. Moh MC, Lee LH, Yang X, Shen S: Hepn1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in hepg2 cells. J Hepatol 2003;39:580-586.
14. Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu JI: Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 2001;49:857-863.
15. Pscherer A, Schliwka J, Wildenberger K, Mincheva A, Schwaenen C, Dohner H, Stilgenbauer S, Lichter P: Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: Application in mantle cell lymphoma. FASEB J 2006;20:1188-1190.
16. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, Oyesiku NM: Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2001;86:3097-3107.
17. Morris DG, Musat M, Czirjak S, Hanzely Z, Lillington DM, Korbonits M, Grossman AB: Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 2005;153:143-151.
18. Sambaziotis D, Kapranos N, Kontogeorgos G: Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas. Pituitary 2003;6:127-133.
19. Moll UM, Wolff S, Speidel D, Deppert W: Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005;17:631-636.
20. Ikeda M, Hirabayashi S, Fujiwara N, Mori H, Kawata A, Iida J, Bao Y, Sato Y, Iida T, Sugimura H, Hata Y: Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspaseindependent pathways. Exp Cell Res 2007;313:1484-1495.
21. Paez-Pereda M, Kuchenbauer F, Arzt E, Stalla GK: Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix. Braz J Med Biol Res 2005;38:1487-1494.
22. Sang QX: Complex role of matrix metalloproteinases in angiogenesis. Cell research 1998;8:171-177.
23. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr: Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993;7:1434-1441.
24. Liu W, Matsumoto Y, Okada M, Miyake K, Kunishio K, Kawai N, Tamiya T, Nagao S: Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Invest 2005;52:151-158.